查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1620557

腦膜炎診斷測試市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Meningitis Diagnostic Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球腦膜炎診斷測試市場於 2023 年達到 1.195 億美元，預計 2024 年至 2032 年複合年成長率為 3.5%。引入創新的治療解決方案。對快速、精確診斷的需求不斷成長，激發了人們對聚合酶鍊式反應 (PCR) 檢測和新一代定序 (NGS) 等先進檢測方法的興趣。這些技術提供了更高的準確性和速度，使醫療保健專業人員能夠從腦脊髓液樣本中識別病原體的遺傳物質。此外，抗生素和疫苗等改進治療方案的開發可以改善患者的治療效果並有助於市場的擴張。

關注腦膜炎意識的公共衛生措施和教育計畫也在推動成長方面發揮重要作用。腦膜炎診斷檢測市場可依檢測類型分類，包括乳膠凝集檢測、側流檢測、PCR檢測、酵素連結免疫吸附檢測（ELISA）、培養檢測和其他方法。 PCR 檢測領域尤其突出，由於其卓越的準確性、靈敏度和快速結果，到 2023 年已達到 4,220 萬美元。按年齡層分析市場時，嬰兒佔有很大佔有率，到 2023 年將佔 39.4%。

此年齡層的檢測通常涉及血液培養和 PCR 檢測，凸顯了快速、靈敏的方法對於減少潛在併發症的重要性。北美腦膜炎診斷檢測市場預計將以 3.3% 的複合年成長率成長，到 2032 年將達到 7,370 萬美元。常見的診斷技術包括 PCR、側流檢測和培養測試，所有這些技術都可以快速、準確地鑑定細菌和病毒株。此外，政府主導的疫苗接種計劃和診斷能力的進步，以及腦膜炎病例的顯著增加，正在推動市場向前發展。診斷檢測產業有望穩定成長。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 1.195 億美元
預測值 1.619 億美元
複合年成長率 3.5%

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球腦膜炎發生率上升
      • 分子診斷技術的進步
      • 提高早期診斷和治療意識
    • 產業陷阱與挑戰
      • 先進診斷測試的高成本
      • 診斷工具獲得嚴格的監管批准
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

  • 主要趨勢
  • 乳膠凝集試驗
  • 側流層析
  • PCR檢測
  • 酵素連結免疫吸附試驗
  • 文化測試
  • 其他測試類型

第 6 章：市場估計與預測：按年齡分類，2021 - 2032

  • 主要趨勢
  • 嬰兒
  • 孩子們
  • 青少年
  • 年輕人
  • 成年人

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷中心
  • 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biomerieux
  • Bio-Rad Laboratories
  • Certest Biotec
  • ELITechGroup
  • F. Hoffmann-La Roche
  • IMMY
  • Seegene
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Uniogen
簡介目錄
Product Code: 11874

The Global Meningitis Diagnostic Testing Market reached USD 119.5 million in 2023 and is anticipated to grow at a CAGR of 3.5% from 2024 to 2032. This growth is driven by several critical factors, including the rising incidence of meningitis, advancements in diagnostic technologies, and the introduction of innovative therapeutic solutions. The increasing demand for swift and precise diagnosis has spurred interest in advanced testing methods, such as polymerase chain reaction (PCR) assays and next-generation sequencing (NGS). These technologies offer heightened accuracy and speed, allowing healthcare professionals to identify the genetic material of pathogens from cerebrospinal fluid samples. Additionally, the development of improved treatment options, such as antibiotics and vaccines, enhances patient outcomes and contributes to the market's expansion.

Public health initiatives and educational programs focused on meningitis awareness also play a significant role in driving growth. The meningitis diagnostic testing market can be categorized by test type, including latex agglutination tests, lateral flow assays, PCR assays, enzyme-linked immunosorbent assays (ELISA), culture tests, and other methods. The PCR assay segment is particularly prominent, having reached USD 42.2 million in 2023 due to its exceptional accuracy, sensitivity, and rapid results. When analyzing the market by age group, infants represent a substantial share, accounting for 39.4% share in 2023. This demographic is especially vulnerable to meningitis, necessitating early and effective diagnostic approaches to address the risks associated with bacterial infections.

Testing for this age group often involves blood cultures and PCR tests, highlighting the importance of quick and sensitive methodologies to reduce potential complications. The North American meningitis diagnostic testing market is expected to grow at 3.3% CAGR, reaching USD 73.7 million by 2032. The U.S. market benefits from a robust healthcare infrastructure, heightened awareness of meningitis, and increased healthcare investments. Common diagnostic techniques include PCR, lateral flow assays, and culture tests, all of which provide rapid and precise identification of bacterial and viral strains. Moreover, government-led vaccination initiatives and advancements in diagnostic capabilities, alongside a notable rise in meningitis cases, are propelling the market forward.Overall, the meningitis diagnostic testing sector is poised for steady growth, driven by technological innovations and a heightened focus on effective healthcare solutions.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$119.5 Million
Forecast Value$161.9 Million
CAGR3.5%

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of meningitis globally
      • 3.2.1.2 Technological advancements in molecular diagnostics
      • 3.2.1.3 Increasing awareness about early diagnosis and treatment
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of advanced diagnostic tests
      • 3.2.2.2 Stringent regulatory approvals for diagnostic tools
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Latex agglutination tests
  • 5.3 Lateral flow assay
  • 5.4 PCR assay
  • 5.5 ELISA tests
  • 5.6 Culture test
  • 5.7 Other test types

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Infants
  • 6.3 Children
  • 6.4 Adolescents
  • 6.5 Young adults
  • 6.6 Adults

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Becton, Dickinson and Company
  • 9.3 Biomerieux
  • 9.4 Bio-Rad Laboratories
  • 9.5 Certest Biotec
  • 9.6 ELITechGroup
  • 9.7 F. Hoffmann-La Roche
  • 9.8 IMMY
  • 9.9 Seegene
  • 9.10 Siemens Healthineers
  • 9.11 Thermo Fisher Scientific
  • 9.12 Uniogen